Sign up
Pharma Capital

Dimerix to lift cash following visit to World Congress for Clinical Trials in Diabetes

The halt will remain in place until Tuesday 5th December 2017.
1512086531_shutterstock_327696869.jpg
The company's shares are in pre-open

Dimerix Ltd (ASX:DXB) is a clinical stage biotechnology company, and has just finished presenting at the World Congress for Clinical Trials in Diabetes in Germany.

Kathy Harrison, chief executive officer for Dimerix, commented:

"These types of conferences are key to showcasing the DMX-200 program on the world stage, and are important for its commercialisation.

"We are grateful to have been given both a poster and oral presentation to promote the impact that DMX200 had on patients in our phase 2a trial."

DMX-200 in an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease.

According to the 2017 US Center for Disease Control Chronic Kidney Disease Fact Sheet, around 44% of new diagnosis of Chronic Kidney Disease in the U.S. is due to diabetes.

To fund the next steps, Dimerix is now heading to market with a capital raising, and the ASX has granted a trading halt to prepare.

The halt will remain in place until the opening of trade on Tuesday 5th December 2017, or earlier if an announcement is made to the market.



Register here to be notified of future DXB Company articles
View full DXB profile

Dimerix Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.